In short. Pain, bruising, infection introduced during preparation and the variability of the material, with the treatments that have clearer evidence beside it.
Key points
- Using the patient’s own blood removes the risk of transmitting an infection from a donor and the risk of an immune reaction to a foreign substance.
- Those are genuine advantages and they are two specific risks.
- The risk of what happens during preparation is not affected by where the blood came from.
The risks here are not dramatic and they come from an unusual place. The material is the person’s own, and the risk is in what happens to it between the arm and the target.
Infection introduced during preparation
This is the recognised risk of a point-of-care biologic and it follows from the same property that makes the material attractive. Blood handled outside a controlled laboratory is a medium in which bacteria grow readily, and a preparation that sits before it is used gives them time. The variables are the environment, the technique, the equipment and the interval, and none of them is governed by a product standard because there is no product. It is a risk that belongs to the process, which is why the process is worth asking about.
Discomfort, bruising and swelling
An injection into the scalp or the face is uncomfortable, and where the treatment is given across a wide area the discomfort and the swelling can be more noticeable than at a single site. Bruising is common and it depends on the instruments and the technique. None of these is removed by the material being autologous.
Autologous removes two risks, not risk
Using the patient’s own blood removes the risk of transmitting an infection from a donor and the risk of an immune reaction to a foreign substance. Those are genuine advantages and they are two specific risks. The risk of what happens during preparation is not affected by where the blood came from.
The variability as a risk
Because the composition depends on the protocol and no standard applies, a person cannot know from the name of the treatment what was injected. That is a risk of a different kind, and it is a real one: it makes comparing clinics impossible, makes a quoted study difficult to apply, and means that an unsatisfactory result cannot be traced to a defined material.
The alternatives
Doing nothing belongs first, particularly where the concern is hair, because hair loss is often progressive and a repeated procedure is a long commitment to an uncertain result. For hair loss, established medical treatments exist that are taken or applied rather than injected, and the comparison worth having is with those rather than with nothing. Where facial volume or shape is the goal, a filler is the treatment designed for it, and a dissolvable gel filler has the further advantage of being correctable with an enzyme if the result is unwanted. Where skin quality is the goal, other options exist with their own evidence and this review does not rank them. A decision that a treatment whose concentration varies and whose evidence is mixed is not worth the commitment is a decision rather than a gap in a plan.
Before agreeing to a course of treatment
- What is this expected to do that another option would not, and on what evidence?
- What is the protocol here, and how long passes between drawing the blood and injecting it?
- How many sessions are proposed, over what period, and what happens if the first few change nothing?
Which option applies is an individual clinical question, and this review does not answer it for anyone. It exists so that the process, the transience and the alternatives are visible before the decision rather than after it.
Frequently asked questions
What are the main risks of PRP?
Infection introduced during preparation, because blood handled outside a controlled laboratory is a medium in which bacteria grow. Bruising, swelling and discomfort also apply, and in the scalp the treatment is usually given across a wide area, so the discomfort and swelling can be more noticeable than at a single site.
Does being autologous remove the risks?
It removes the risk of transmitting an infection from a donor and the risk of an immune reaction to a foreign substance. Those are two specific risks and removing them is genuinely valuable. It does not remove the risk of infection introduced during preparation, nor bruising, swelling or an unsatisfactory result.
What are the alternatives?
For hair loss, established medical treatments exist that are taken or applied rather than injected, and they have their own evidence and limits. For facial volume, a filler is the treatment designed for it and a dissolvable gel filler can be broken down with an enzyme. Doing nothing is also an option, and a genuine one where the concern is progressive.
Risks & Limitations
- There is no cosmetic approval, and no authority has assessed the claims made for the treatment.
- The platelet concentration depends on the kit, device and spin used, and is not standardised or comparable between clinics.
- Blood handled outside a controlled laboratory is a medium in which bacteria grow, so preparation carries a risk of infection that the source of the blood does not remove.
- The material is reabsorbed over a short period, so it does not restore volume the way a filler does.
- Adding it to another treatment is not evidence that the combination works better than the main treatment alone.
When to Seek Care
- Redness, warmth, swelling or pain that is increasing rather than settling after an injection.
- Discharge from an injection site, or a fever — seek prompt clinical assessment.
- An uneven or lumpy result, or any change in the treated area that concerns you.
- Contact the service that performed the treatment, or the hospital’s outpatient channels, rather than relying on a website.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — guidance on autologous cellular products and point-of-care preparation
- European Medicines Agency (EMA) and national regulators — guidance on blood-derived and autologous treatments
- National Medical Products Administration (NMPA, China) — regulation of blood-derived preparations and devices
- World Health Organization (WHO) — guidance on the safe preparation and handling of blood components
- Cochrane Library — systematic reviews of platelet-rich plasma for hair loss and skin indications
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.